Vanguard Global Advisers
ELTX icon

Vanguard Global Advisers’s Elicio Therapeutics ELTX Stock Holding History

Vanguard Global Advisers’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.3K Hold
4,416
– – ﹤0.01% 3373
2026
Q1 		$47.2K Buy
+4,416
New +$42.6K ﹤0.01% 3051

Other funds holding ELTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Global Advisers's ELTX Position: Q2 2026 in Review

Vanguard Global Advisers held its Elicio Therapeutics (ELTX) position steady in Q2 2026 at 4,416 shares worth $17.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3373.

Vanguard Global Advisers first reported a position in ELTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $47.2K in Q1 2026. 46 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • Vanguard Global Advisers held 4,416 shares of Elicio Therapeutics worth $17.3K as of Q2 2026.
  • Vanguard Global Advisers left its Elicio Therapeutics share count unchanged in Q2 2026.
  • Elicio Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3373 holding.
  • Vanguard Global Advisers first reported a position in Elicio Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Elicio Therapeutics position peaked at $47.2K in Q1 2026.
  • 46 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.